Our health care roundtable gathers the Motley Fool's top health care analysts to discuss the sector's biggest stories in a free flowing and highly opinionated format.
In this portion of the video, the guys discuss one of Johnson & Johnson's major acquisitions in the medical devices space and whether it was a good idea considering that the company has seen some slowdown in that area. They discuss the huge potential with rapidly growing emerging markets and the difficulty in tapping those markets when the people there simply don't have as much money to spend.
In the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. Offering everything from baby powder to biologics, critics think the company has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand new premium report on Johnson & Johnson. To claim your copy simply click here now for instant access.
The article Emerging Markets Health Care -- A Unique Challenge originally appeared on Fool.com.Brenton Flynn and David Williamson have no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson and Medtronic and has the following options: short MAY 2013 $44.00 calls on Medtronic. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.